BR112022006381A2 - Pró-fármacos de inibidores de mieloperoxidase - Google Patents

Pró-fármacos de inibidores de mieloperoxidase

Info

Publication number
BR112022006381A2
BR112022006381A2 BR112022006381A BR112022006381A BR112022006381A2 BR 112022006381 A2 BR112022006381 A2 BR 112022006381A2 BR 112022006381 A BR112022006381 A BR 112022006381A BR 112022006381 A BR112022006381 A BR 112022006381A BR 112022006381 A2 BR112022006381 A2 BR 112022006381A2
Authority
BR
Brazil
Prior art keywords
prodrugs
myeloperoxidase
myeloperoxidase inhibitor
mpo
inhibitor prodrugs
Prior art date
Application number
BR112022006381A
Other languages
English (en)
Portuguese (pt)
Inventor
M Dubowchik Gene
Theodore Lundquist Joseph Iv
A Mcwherter Melody
C Pelletier Jeffrey
B Reitz Allen
Strobel Eric
Zhang Yan
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of BR112022006381A2 publication Critical patent/BR112022006381A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
BR112022006381A 2019-10-10 2020-10-09 Pró-fármacos de inibidores de mieloperoxidase BR112022006381A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913417P 2019-10-10 2019-10-10
PCT/US2020/054896 WO2021072140A1 (en) 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors

Publications (1)

Publication Number Publication Date
BR112022006381A2 true BR112022006381A2 (pt) 2022-06-28

Family

ID=75438074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006381A BR112022006381A2 (pt) 2019-10-10 2020-10-09 Pró-fármacos de inibidores de mieloperoxidase

Country Status (11)

Country Link
US (1) US20240067651A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041735A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022552834A (cg-RX-API-DMAC7.html)
KR (1) KR20220080133A (cg-RX-API-DMAC7.html)
CN (1) CN114945573A (cg-RX-API-DMAC7.html)
AU (1) AU2020363903A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006381A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157260A1 (cg-RX-API-DMAC7.html)
IL (1) IL291891A (cg-RX-API-DMAC7.html)
MX (1) MX2022004203A (cg-RX-API-DMAC7.html)
WO (1) WO2021072140A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010902A (es) * 2020-03-05 2022-10-07 Biohaven Therapeutics Ltd Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012797A1 (en) * 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sulfer-containing xanthine derivatives as adenosin antagonists
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2007069924A1 (en) * 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
SG11202000086PA (en) * 2017-07-17 2020-02-27 Astrazeneca Ab Mpo inhibitors for use in medicine

Also Published As

Publication number Publication date
JP2022552834A (ja) 2022-12-20
AU2020363903A1 (en) 2022-03-24
MX2022004203A (es) 2022-07-04
CA3157260A1 (en) 2021-04-15
EP4041735A4 (en) 2023-11-22
IL291891A (en) 2022-06-01
KR20220080133A (ko) 2022-06-14
CN114945573A (zh) 2022-08-26
WO2021072140A1 (en) 2021-04-15
US20240067651A1 (en) 2024-02-29
EP4041735A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
WO2019191229A8 (en) Compounds for treating huntington's disease
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
BR112022007947A2 (pt) Uso de modulador de splicing para tratamento que retarda a progressão da doença de huntington
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MY155633A (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
CO2022009787A2 (es) Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
MX2021006347A (es) Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR112021018254A2 (pt) Derivados de nicorandil
BRPI0919057A2 (pt) compostos de indazol ou derivados, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento ou profilaxia de enfermidades que são afetadas por moduladores de fxr, e uso dos compostos
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
BR112022009086A2 (pt) Inibidores alostéricos de egfr e métodos de uso dos mesmos
MX2024009773A (es) Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
BR112023017713A2 (pt) Composições compreendendo profármacos cliváveis por enzima e nafamostato de liberação controlada e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2848 DE 05-08-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.